Company continues to drive growth through key platform enhancements, customer-focused innovations, and strategic expansion in genomic healthcare technology.
[BOSTON] – February 20, 2025 – Velsera, a leading global healthcare technology company offering a universal software platform to connect clinical care with discovery, today reflected on a number of key achievements to date that have driven substantial growth in 2024. Velsera’s momentum is fueled by key platform enhancements, expansion of clinical decision support, and customer-centric innovations and services.
“2024 marked an incredible year for Velsera, as we continued to enhance our flagship platforms and introduce new customer-centric initiatives,” said Jamie Littlejohns, CEO of Velsera. “Looking ahead to 2025, Velsera is ready to lead the charge in multi-omics analytics and precision health, redefining how organizations harness the power of genomic data to improve clinical outcomes and advance precision medicine.”
Key Platform Updates and Enhancements
Velsera made significant progress with the launch of its CGW Plus, an enhanced version of the Clinical Genomics Workspace (CGW) platform. This updated platform introduces advanced workflows for variant quality assessment and clinical evidence review, designed to simplify and accelerate the analysis and reporting of genetic sequence data for clinical laboratory professionals.
“The CGW Plus platform has already proved to be a game-changer for healthcare providers by greatly streamlining genomic data management, analysis, interpretation, and reporting processes,” said Rakesh Nagarajan, MD, PhD, Chief Medical Officer at Velsera. “These enhancements are a direct result of Velsera’s ongoing commitment to understanding and addressing customer needs, ensuring that we continue to lead innovation in genomic healthcare.”
Customer-Centric Innovations and Services
Throughout 2024, Velsera made a concerted effort to enhance customer experience by introducing several important initiatives:
- Creation of a New Customer Success Management Team: A dedicated team to ensure customers receive tailored support and guidance throughout their journey with Velsera, helping them fully leverage the company’s solutions.
- Launch of a Customer Experience Framework: A standardized framework within Velsera’s support organization to provide a seamless and consistent experience across all customer touchpoints.
- Redesign of Services Packages: Based on insights from 180 customer implementations, Velsera redesigned its services packages to meet the needs of its customers for their specific situation.
- Consolidation of Product Documentation: Unifying product documentation, training materials, and support resources into one comprehensive user experience.
- Introduction of a Self-Paced Training Platform: A new, role-based training platform that offers flexible learning options for customers to deepen their knowledge of Velsera’s products.
“Customer success is at the core of our business, and in 2024, we made key strides in ensuring that they receive exceptional support,” said Julie Furt, Chief Customer Officer of Velsera. With these initiatives in place, Velsera is providing its customers with the tools and resources they need to succeed, and we’re excited to continue this momentum into 2025 and beyond, furthering our commitment to bridging health and science for a healthier tomorrow.
Optimized Support of Nextflow Workflow Language
A strong example of Velsera’s dedication to customer needs was the complete overhaul and optimization of our Nextflow support in 2024, launched at the Nextflow Summit in Barcelona. The Nextflow developer community is vibrant and expanding, with a suite of best-practice workflows in nf-core. The Bioinformatics community across pharma, biotech, and academia are increasingly adopting Nextflow support.
Moreover, Velsera greatly optimized multiple nf-core workflows to deliver unmatched speed and cost-efficiency, improved the overall performance of the executor, fully integrated Nextflow into its analysis platform, and upgraded the user experience. These improvements were guided by customer feedback and Velsera’s decade-long expertise in workflow optimization.
Future Outlook
Velsera remains committed to expanding the capabilities of its CGW Plus platform in 2025, with a strong focus on enhancing decision support services and building strategic partnerships to drive its growing leadership position in the genomic and healthcare technology sector. With its customer-centric approach, Velsera is positioned to revolutionize how organizations leverage genomic data to improve clinical outcomes, advancing the next generation of precision medicine and contributing to a healthier future.
Upcoming Events
Don’t miss our upcoming webinar: Join us on February 27th at 8 a.m. PST/11 a.m. EST/4 p.m. GMT for “The Story of ARIA,” presented by Dr. Sarah E. Kleinstein, PhD, MS. Discover how ARIA transforms multi-modal data into actionable insights and accelerates scientific discoveries. Register now.
Attending the 2025 Annual Clinical Genetics meeting? Our team will be at ACMG from March 19-21—stop by booth #708 to meet us and learn more about how we can support your goals.
To learn more about Velsera and its innovative solutions, please visit https://velsera.com/.
About Velsera
Velsera’s mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help experts in clinical diagnostics and life sciences make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 as a result of the merger of Seven Bridges, PierianDx and UgenTec and operates in the US, Europe and Asia.
Contact:
Velsera
Brian Lassiter
brian.lassiter@velsera.com